Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 11Dermatologic 5CNS 5Thoracic 2Lymphoid 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Endometrial Adenocarcinoma 1

Interventions

Carboplatin 62Paclitaxel 61Specimen Handling 37Cisplatin 37Taxes 35Magnetic Resonance Spectroscopy 31Bevacizumab 30Immunoglobulin G 23Disulfides 23Biopsy 22Cyclophosphamide 19aldesleukin 17Topotecan 16Brachytherapy 16Radiotherapy 15Gemcitabine 15veliparib 14Oxaliplatin 13Doxorubicin 13temsirolimus 12fludarabine 12Platinum 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 12olaparib 11liposomal doxorubicin 10cediranib 10Sirolimus 10Radiation 9Nivolumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × AZD 6244 × Gynecologic × Clear all
NCT01011933 2019-07-23

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
54 enrolled 13 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡